Phase ii study of lonidamine in metastatic breast cancer


Play all audios:

ABSTRACT Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for


response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39%


of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and


toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy. Access through your institution Buy or subscribe This is a preview of subscription content, access via your


institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this


article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in


* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS NEOADJUVANT STUDY OF NIRAPARIB IN PATIENTS WITH HER2-NEGATIVE,


_BRCA_-MUTATED, RESECTABLE BREAST CANCER Article Open access 04 July 2022 A PHASE 1B OPEN-LABEL STUDY OF GEDATOLISIB (PF-05212384) IN COMBINATION WITH OTHER ANTI-TUMOUR AGENTS FOR PATIENTS


WITH ADVANCED SOLID TUMOURS AND TRIPLE-NEGATIVE BREAST CANCER Article 05 November 2022 ENTINOSTAT, NIVOLUMAB AND IPILIMUMAB FOR WOMEN WITH ADVANCED HER2-NEGATIVE BREAST CANCER: A PHASE IB


TRIAL Article 14 February 2024 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy P Pronzato Authors * P


Pronzato View author publications You can also search for this author inPubMed Google Scholar * D Amoroso View author publications You can also search for this author inPubMed Google


Scholar * G Bertelli View author publications You can also search for this author inPubMed Google Scholar * PF Conte View author publications You can also search for this author inPubMed 


Google Scholar * MP Cusimano View author publications You can also search for this author inPubMed Google Scholar * GB Ciottoli View author publications You can also search for this author


inPubMed Google Scholar * M Gulisano View author publications You can also search for this author inPubMed Google Scholar * R Lionetto View author publications You can also search for this


author inPubMed Google Scholar * R Rosso View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS


ARTICLE CITE THIS ARTICLE Pronzato, P., Amoroso, D., Bertelli, G. _et al._ Phase II study of lonidamine in metastatic breast cancer. _Br J Cancer_ 59, 251–253 (1989).


https://doi.org/10.1038/bjc.1989.51 Download citation * Issue Date: 01 February 1989 * DOI: https://doi.org/10.1038/bjc.1989.51 SHARE THIS ARTICLE Anyone you share the following link with


will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt


content-sharing initiative